TKIs are designed to inhibit the kinase activity of these dysregulated TKs, preventing the phosphorylation of tyrosine residues on substrate proteins and, thus, halting the downstream signaling pathways that drive cancer cell proliferation. This evidence concerns the gene CDC42 and cancer.